07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Diamyd Medical endocrine/metabolic, cancer, neurology news

Diamyd Medical spun out its Diamyd Therapeutics AB subsidiary, which was renamed Diamyd Medical AB, as part of a liquidation process announced in February. The former Diamyd Medical changed its name to Mertiva AB and...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Diamyd Medical endocrine/metabolic news

Diamyd said it has reached an agreement with the group of shareholders proposing the company enter into immediate liquidation. Under the agreement, Diamyd will distribute the company's "excess cash," or about SEK300 million ($47 million),...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Diamyd Medical endocrine/metabolic news

Diamyd said it will convene an extraordinary general meeting on March 13 to address a proposal from a group of shareholders that Diamyd enter into immediate liquidation. The shareholders, which claim to represent 8.9 million...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Financial News

Diamyd financial update

Diamyd said the proposal regarding a stock dividend did not reach the required majority at the company's extraordinary general meeting and thus has lapsed. The company, which closed at SEK12.10, on Friday, has 28.1 million...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Clinical News

Diamyd: Phase II start

This month, Diamyd said that Linkoping University will begin the 30-month, double-blind, Swedish Phase II DIABGAD-1 trial to evaluate Diamyd in 60 Type I diabetics ages 10-18 years. Patients will receive a prime injection of...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Financial News

Diamyd financial update

Diamyd's shareholders authorized the repurchase of up to 3 million series B shares. The company, which closed at SEK9.95 on Friday, has 29.6 million shares outstanding. Diamyd Medical AB (SSE:DIAM B), Stockholm, Sweden   Business:...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Financial News

Diamyd financial update

Diamyd will seek approval at its extraordinary general meeting in the second half of January to repurchase up to SEK118.3 million ($17.8 million) in shares at SEK12. The company, which closed at SEK9.60 on Friday,...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

Diamyd Medical endocrine/metabolic news

Diamyd will allocate up to SEK30 million ($4.5 million) over the next three years to develop diabetes candidate Diamyd. Diamyd plans to provide data within three years for partnering or other funding. Last year, Diamyd...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Diamyd Medical, Periphagen Holdings deal

Diamyd will sell its U.S. subsidiary Diamyd Inc. to Periphagen for $1 and a holding of 10% in Periphagen. As part of the deal, Periphagen will acquire IP rights to Diamyd's Nerve Targeting Drug Delivery...
07:00 , Jul 9, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell $0.60 (41%) to $0.87 on Tuesday after it said FDA recommended the company conduct an additional trial for Northera droxidopa to support an NDA resubmission to treat...